2.17 -0.01 (-0.46%)
After hours: 6:23PM EDT
|Bid||2.16 x 900|
|Ask||2.24 x 800|
|Day's Range||1.99 - 2.25|
|52 Week Range||1.86 - 4.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.67|
AVEO Oncology (AVEO) today issued the following statement regarding its recently revised guidance on the timing of topline data from the TIVO-3 study, its Phase 3 trial of tivozanib as a third-line treatment for advanced renal cell carcinoma. “The Company expects to report topline results from the TIVO-3 study in the fourth quarter of 2018, approximately 6-8 weeks after the trial records 255 progression free survival (PFS) events. The one-time adjustment in the event count is the result of an administrative error that occurred from counting, as PFS events, the deaths of ten patients who had left the study without documented radiographic progression.
Yesterday, Aveo Pharmaceuticals (AVEO) issued an 8-K filing reporting its plan to release top-line data from its Phase 3 trial TIVO-3 in Q4 2018. In the US Phase 3 registrational study, the company is examining the vascular endothelial growth factor receptor (or VEGFR) 123 tyrosine kinase inhibitor (or TKI) Fotivda (tivozanib) for third-line advanced renal cell carcinoma (or RCC).
NEW YORK, NY / ACCESSWIRE / July 18, 2018 / Shares of AVEO Pharmaceuticals were deep in the red on Tuesday after a SEC 8-K revealed that the company’s TIVO-3 data is now delayed until the fourth quarter. Shares of ACADIA Pharmaceuticals were in the green despite any news. AVEO Pharmaceuticals, Inc. shares closed down 24.21% on Tuesday with nearly 9.4 million shares traded.
NEW YORK, June 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Six ...
LONDON, UK / ACCESSWIRE / June 25, 2018 / If you want a free Stock Review on AVEO sign up now at www.wallstequities.com/registration. Last Friday, shares in Cambridge, Massachusetts-based AVEO Pharmaceuticals Inc. ended the session 4.35% higher at $2.40.
AVEO Oncology (AVEO) today announced that it has been added to the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes, effective after the U.S. market closed on Friday, June 22, 2018 as part of FTSE’s annual reconstitution. “We believe that inclusion in the widely referenced Russell U.S. Indexes reflects the significant progress we have made as a Company in the last year, including European approval of tivozanib for the treatment of adult patients with advanced kidney cancer,” said Michael Bailey, president and chief executive officer of AVEO. Annual Russell U.S. Indexes reconstitution captures the 4,000 largest US stocks as of May 11, ranking them by total market capitalization.
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
AVEO Pharmaceuticals (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AVEO Oncology (AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Jefferies 2018 Healthcare Conference in New York on Thursday, June 7, 2018 at 9:30 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need.
LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want a free Stock Review on AVEO, CLDX, and CERS sign up now at www.wallstequities.com/registration. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Audentes Therapeutics Inc. (NASDAQ: BOLD), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Cerus Corp. (NASDAQ: CERS).
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the first quarter while revenues come almost in-line with estimates. Data from TIVO-3 study postponed. Shares down.
NEW YORK, May 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of F.N.B. ...
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is attracting a substantial amount of attention in the biotechnology space early morning out of Europe this week, with the company moving on and update related to one of its lead development assets in the sector. Here is a look at what happened and why it is important for AVEO and […] The post Here Is What Just Happened With Aveo Pharmaceuticals appeared first on Market Exclusive.
AVEO Oncology today reported financial results for the first quarter ended March 31, 2018 and provided a business update.
AVEO Pharmaceuticals' (AVEO) first drug, Fotivda for the first-line treatment of RCC is likely to have a favorable impact on first-quarter results.
NEW YORK, NY / ACCESSWIRE / April 6, 2018 / U.S. markets ended higher on Thursday for their third straight daily gain as technology stocks recover from a series of shortcomings. The Dow Jones Industrial ...
AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences:
AVEO Pharmaceuticals (AVEO) needs investors to pay close attention to the stock based on moves in the options market lately.
AVEO Oncology today announced the publication of long-term follow-up results from Study 902, where patients were treated with tivozanib as second-line treatment in advanced renal cell carcinoma , in the European Journal of Cancer.
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the fourth quarter with revenues missing estimates. The top line also declines year over year.